FDA approved in October, 2012, BETHKIS® is used by people with cystic fibrosis to improve lung function, treat Pseudomonas aeruginosa infection, and improve quality of life. People who use BETHKIS® also gain weight and are less likely to need hospitalization. BETHKIS® is administered with short, convenient nebulizer treatments.
BETHKIS® contains 300 mg of tobramycin in only four mL of solution. Because it is delivered directly to the lungs, BETHKIS® is able to better combat infection. BETHKIS® disrupts protein synthesis in Pseudomonas aeruginosa, killing the bacteria.
The medication is taken in repeated cycles of 28 days of daily treatment and 28 days off. People continue to see benefits during the 28-day period where they are not taking the medication.
This treatment was designed to specifically target Pseudomonas aeruginosa, one of the most dangerous bacteria for people with cystic fibrosis. Access to BETHKIS® is just one piece of the full service cystic fibrosis treatments available from IV Solutions.
Components of BETHKIS® (Tobramycin)
BETHKIS® arrives in plastic ampules inside a foil pouch. Each ampule contains one dose. The medication is squeezed into a PARI LC PLUS nebulizer connected to a PARI Vios compressor. Treatments last about 15 minutes. Refer to the image on the left to see what comes in BETHKIS® Welcome Kit.
Tips for taking BETHKIS®
- BETHKIS® is not approved for children under six years of age
- Keep the medication in the foil package and store it in the refrigerator
- Continue your treatment until your nebulizer has made a spitting noise for a full minute
- For best results, clean your nebulizer regularly
- Follow your doctor’s instructions and use BETHKIS® only as directed
BETHKIS® is a registered trademark of Chiesi Farmaceutici, S.p.A.
Click here for full prescribing information of BETHKIS®
Further resources regarding BETHKIS®